Pathology: mML - L2 - all population;
mML - L2 - all population | |||||||
Ascierto (ipi 10 vs 3 mg/kg), 2017 | CA184-004, 2011 | MDX010 Ipi vs gp100, 2010 | MDX010 Ipi plus gp100 vs gp100, 2010 | MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 | CA184-024, 2011 | ||
Ipilimumab (10 mg/kg) | 2 | T1 | T1 | ||||
ipilimumab plus gp100 | 2 | T1 | T1 | ||||
ipilimumab alone | 1 | T0 | T0 | T1 | T0 | ||
ipilimumab plus SoC | 1 | T1 | |||||
placebo plus SoC | 0 | T0 | |||||
gp100 | 0 | T0 | T0 |